Table 1 Characteristics of patients with BP-associated cardiac arrhythmias sourced from the FAERS database (January 2016 to June 2022).
Characteristics | Â | Total reports, n (%) | Fatal cases, n (%) | Non-fatal cases, n (%) | p-value |
|---|---|---|---|---|---|
Total | Â | 2377 | 866 | 1511 | Â |
Patient age (year) | — |  |  |  | 0.075 |
|  | Median (IQR) | 70(59–78) | 71(64–78) |  |  |
| Â | < 18 | 62(2.61%) | 15(1.73%) | 47(3.11%) | Â |
|  | 18–64 | 551(23.18%) | 153(17.67%) | 398(26.34%) |  |
|  | 65–74 | 566(23.81%) | 233(26.91%) | 333(22.04%) |  |
|  | ≥ 75 | 613(25.79%) | 240(27.71%) | 373(24.69%) |  |
| Â | Unknown | 585(24.61%) | 225(25.98%) | 360(23.83%) | Â |
Gender | — |  |  |  | NS |
| Â | Female | 1471(61.88%) | 485(56.00%) | 986(65.25%) | Â |
| Â | Male | 666(28.02%) | 246(28.41%) | 420(27.80%) | Â |
| Â | Unknown | 240(10.10%) | 135(15.59%) | 105(6.95%) | Â |
Reporting year | — |  |  |  | 0.021 |
| Â | 2016 | 248(10.43%) | 63(7.27%) | 185(12.24%) | Â |
| Â | 2017 | 258(10.85%) | 50(5.77%) | 208(13.77%) | Â |
| Â | 2018 | 339(14.26%) | 89(10.28%) | 250(16.55%) | Â |
| Â | 2019 | 375(15.78%) | 79(9.12%) | 296(19.59%) | Â |
| Â | 2020 | 350(14.72%) | 76(8.78%) | 274(18.13%) | Â |
| Â | 2021 | 423(17.80%) | 146(16.86%) | 277(18.33%) | Â |
| Â | 2022 | 384(16.15%) | 277(31.99%) | 107(7.08%) | Â |
Area | — |  |  |  | 1.000 |
| Â | Africa | 5(0.21%) | 3(0.35%) | 2(0.13%) | Â |
| Â | Asian | 192(8.08%) | 100(11.55%) | 92(6.09%) | Â |
| Â | Europe | 756(31.80%) | 285(32.91%) | 471(31.17%) | Â |
| Â | North America | 1242(52.25%) | 381(44.00%) | 861(56.98%) | Â |
| Â | Oceania | 38(1.60%) | 7(0.81%) | 31(2.05%) | Â |
| Â | South America | 81(3.41%) | 34(3.93%) | 47(3.11%) | Â |
| Â | Unknown | 63(2.65%) | 56(6.47%) | 7(0.46%) | Â |
Reporters | — |  |  |  | 0.251 |
| Â | Physician | 719(30.25%) | 276(31.87%) | 443(29.32%) | Â |
| Â | Pharmacist | 188(7.91%) | 56(6.47%) | 132(8.74%) | Â |
|  | Other health–professional | 834(35.09%) | 331(38.22%) | 503(33.29%) |  |
|  | Lawyer, Consumer or Non–health professional | 609(25.62%) | 194(22.40%) | 415(27.47%) |  |
| Â | Unknown | 27(1.14%) | 9(1.04%) | 18(1.19%) | Â |
BP as suspected drug | — |  |  |  | 0.306 |
| Â | Zoledronic acid | 1020(42.91%) | 361(41.69%) | 659(43.61%) | Â |
| Â | Risedronate sodium | 352(14.81%) | 172(19.86%) | 180(11.91%) | Â |
| Â | Ibandronate sodium | 85(3.58%) | 15(1.73%) | 70(4.63%) | Â |
| Â | Alendronate sodium | 823(34.62%) | 295(34.06%) | 528(34.94%) | Â |
| Â | Pamidronate disodium | 49(2.06%) | 16(1.85%) | 33(2.18%) | Â |
| Â | Clodronate disodium | 7(0.29%) | 1(0.12%) | 6(0.40%) | Â |
| Â | Etidronate disodium | 41(1.72%) | 6(0.69%) | 35(2.32%) | Â |
